- Home
- KLAR vs GEHC Comparison
KLAR vs GEHC Comparison
Compare KLAR & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLAR
- GEHC
- Stock Information
- Founded
- KLAR 2005
- GEHC 1892
- Country
- KLAR United Kingdom
- GEHC United States
- Employees
- KLAR N/A
- GEHC N/A
- Industry
- KLAR Finance: Consumer Services
- GEHC Computer Software: Prepackaged Software
- Sector
- KLAR Finance
- GEHC Technology
- Exchange
- KLAR Nasdaq
- GEHC Nasdaq
- Market Cap
- KLAR 30.9B
- GEHC 32.9B
- IPO Year
- KLAR 2025
- GEHC N/A
- Fundamental
- Price
- KLAR N/A
- GEHC $77.48
- Analyst Decision
- KLAR Buy
- GEHC Strong Buy
- Analyst Count
- KLAR 2
- GEHC 9
- Target Price
- KLAR $53.00
- GEHC $89.00
- AVG Volume (30 Days)
- KLAR 16.8M
- GEHC 3.1M
- Earning Date
- KLAR 01-01-0001
- GEHC 10-29-2025
- Dividend Yield
- KLAR N/A
- GEHC 0.17%
- EPS Growth
- KLAR N/A
- GEHC 41.40
- EPS
- KLAR N/A
- GEHC 4.88
- Revenue
- KLAR $3,009,058,798.00
- GEHC $19,967,000,000.00
- Revenue This Year
- KLAR N/A
- GEHC $6.09
- Revenue Next Year
- KLAR N/A
- GEHC $4.65
- P/E Ratio
- KLAR N/A
- GEHC $15.92
- Revenue Growth
- KLAR 19.78
- GEHC 2.31
- 52 Week Low
- KLAR $40.25
- GEHC $57.65
- 52 Week High
- KLAR $57.20
- GEHC $94.80
- Technical
- Relative Strength Index (RSI)
- KLAR N/A
- GEHC 57.30
- Support Level
- KLAR N/A
- GEHC $75.64
- Resistance Level
- KLAR N/A
- GEHC $79.69
- Average True Range (ATR)
- KLAR 0.00
- GEHC 1.87
- MACD
- KLAR 0.00
- GEHC 0.33
- Stochastic Oscillator
- KLAR 0.00
- GEHC 74.15
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).